This covers the pharmacologic and regulatory theory of biosimilars in hematology/oncology: unlike small-molecule generic drugs, which are chemically identical reproductions of a defined structure, biosimilars are complex, large-molecular-weight biologic proteins (e.g., monoclonal antibodies) produced in living cellular systems, making exact molecular replication impossible; a biosimilar is instead defined regulatorily as a product demonstrating equivalent efficacy, safety, and clinically insignificant structural variation relative to an originator biologic, established through analytic characterization followed by head-to-head clinical trials. A secondary theoretical concept addressed is the statistical interpretation of population-derived risk percentages (e.g., progression probabilities) in individual clinical decision-making, distinguishing aggregate/population-level probability from the binary outcome experienced by any single patient.
This covers the pharmacologic and regulatory theory of biosimilars in hematology/oncology: unlike small-molecule generic drugs, which are chemically identical reproductions of a defined structure, bi…